This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Analysts Estimate Patterson Cos. (PDCO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Patterson Cos. (PDCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Patterson Companies' (PDCO) New Launch to Boost Patient Service
by Zacks Equity Research
Patterson Companies' (PDCO) Patterson CarePay+ is likely to improve overall patient care and streamline practice operations.
The Cooper Companies (COO) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 2.41% and 0.56%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Hold Patterson Companies (PDCO) in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
Patterson Cos. (PDCO) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Patterson Cos. (PDCO) give insight into how the company performed in the quarter ended January 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Patterson Companies (PDCO) Misses on Q3 Earnings, Lowers EPS View
by Zacks Equity Research
Patterson Companies' (PDCO) third-quarter fiscal 2024 results reflect an improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales appear weak.
Patterson Cos. (PDCO) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of -1.67% and 1.02%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Patterson Companies (PDCO) in Q3 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.
Patterson Cos. (PDCO) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Evaluate the expected performance of Patterson Cos. (PDCO) for the quarter ended January 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Patterson Cos. (PDCO) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Patterson Cos. (PDCO) closed at $28.40 in the latest trading session, marking a +0.18% move from the prior day.
Patterson Cos. (PDCO) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
Patterson Cos. (PDCO) closed the most recent trading day at $29.09, moving +1.43% from the previous trading session.
Patterson Cos. (PDCO) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Patterson Cos. (PDCO) closed the most recent trading day at $28.97, moving -0.52% from the previous trading session.
Patterson Cos. (PDCO) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
The latest trading day saw Patterson Cos. (PDCO) settling at $30.05, representing a +0.07% change from its previous close.
Patterson Cos. (PDCO) Laps the Stock Market: Here's Why
by Zacks Equity Research
Patterson Cos. (PDCO) concluded the recent trading session at $30.34, signifying a +1.71% move from its prior day's close.
Patterson Cos. (PDCO) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the most recent trading session, Patterson Cos. (PDCO) closed at $30.16, indicating a -0.56% shift from the previous trading day.
Patterson Cos. (PDCO) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the closing of the recent trading day, Patterson Cos. (PDCO) stood at $29.63, denoting a +0.73% change from the preceding trading day.
Why Is Patterson Cos. (PDCO) Up 12.1% Since Last Earnings Report?
by Zacks Equity Research
Patterson Cos. (PDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Patterson Companies (PDCO) Q2 Earnings Miss, EPS View Lowered
by Zacks Equity Research
Patterson Companies' (PDCO) second-quarter fiscal 2024 results reflect improvement in Dental Consumable sales, which were offset by lower Dental Equipment sales. Animal health sales improve.
Compared to Estimates, Patterson Cos. (PDCO) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Patterson Cos. (PDCO) give insight into how the company performed in the quarter ended October 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
What's in Store for Patterson Companies (PDCO) in Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.
Exploring Analyst Estimates for Patterson Cos. (PDCO) Q2 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Patterson Cos. (PDCO) for the quarter ended October 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Patterson Cos. (PDCO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Patterson Cos. (PDCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Patterson Companies (PDCO) Partners With Pearl for AI Services
by Zacks Equity Research
Patterson Companies (PDCO) collaborates with dental AI solution provider, Pearl, to integrate the latter's Second Opinion software solution within its Eaglesoft software to deliver advanced solutions.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Patterson Cos. (PDCO) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
Patterson Cos. (PDCO) closed at $32.03 in the latest trading session, marking a +0.03% move from the prior day.